IL17A and cervical cancer: These results contrast with a previous report, which demonstrated that miR-30a directly targets TRAF3IP2 and blunts IL-17-mediated inflammatory cytokine and chemokine expression in HeLa cells, an immortalized human cervical cancer cell line [48], suggesting that its effects may be cell type-specific.